Clinical and Blood Bank Factors in the Management of Platelet Refractoriness and Alloimmunization

• Published in: Blood 1993-06, Vol.81 (12), p.3428-3434
• Main Authors: Friedberg, Richard C., Donnelly, Sarah F., Boyd, James C., Gray, Lloyd S., Mintz, Paul D.
• Format: Article
• Language: English
• Subjects: Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Biological and medical sciences; Blood Banks; Blood Component Transfusion; Blood Grouping and Crossmatching; Blood Platelets - immunology; Blood Platelets - physiology; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis; Hematologic Diseases - therapy; Histocompatibility Testing; Humans; Immunization; Isoantigens - immunology; Medical sciences; Platelet Count; Prospective Studies; Regression Analysis; Transfusions. Complications. Transfusion reactions. Cell and gene therapy
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V81.12.3428.3428

Numerous independent and interdependent factors are involved in the posttransfusion platelet response. Factors such as ABO match and platelet age are related to circumstances potentially under the control of the blood bank physician and therefore may permit circumvention by an active transfusion service. On the other hand, factors such as fever or sepsis may be unavoidable, being related more to the individual patient or clinical condition. To evaluate which factors could be circumvented, we prospectively followed the 1-hour corrected count increments (CCIs) for 962 single-donor apheresis platelet transfusions to 71 refractory hematologic oncology inpatients, with concomitant recording of implicated factors. Stepwise regression analysis allowed for determination of which concurrent and confounding clinical-, patient-, and blood bank-related factors significantly affected the CCIs. Although many implicated factors proved to be independently associated with an increased or decreased CCI, we found that no single variable consistently explained the CCI variation across the patient population. Each patient appeared sensitive to one or a few particular factors, but because of marked intraindividual variation, it was not possible to identify a priori which factors were important for a given patient. The single exception was a solid-phase red blood cell adherence assay used to cross-match platelets, but only for alloimmunized patients. We also evaluated the utility of requesting FILA-matched platelets from the local suppliers and maintained a clear distinction between platelets simply ordered as HLA matched and actually H LA-identical platelets. Accounting for the confounding clinical-, patient-, and blood bank—related factors, the cross-match assay was a better predictor of an adequate CCI than ordering platelets as FILA matched.